Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Journal of Thrombosis and Thrombolysis
|
November 24, 2021
Management of bone marrow biopsy related bleeding risks: a retrospective observational study
Lucile Grange, Martin Killian, Emmanuelle Tavernier, et al.
Cancer Epidemiology
|
August 15, 2025
Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA
Christelle Cantrelle, Aurélien Belot, Alain Monnereau, et al.
Cancer Epidemiology
|
April 6, 2025
Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort
Christelle Cantrelle, Aurélien Belot, Alain Monnereau, et al.
Blood Cancer Journal
|
November 3, 2025
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials
Valentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, et al.
Leukemia
|
April 24, 2025
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Nicolas Gazeau, David Beauvais, Rémi Tilmont, et al.
Blood Advances
|
December 8, 2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
Raphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, et al.
Clinical Nuclear Medicine
|
June 11, 2021
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells
Pierre Sesques, Jérémie Tordo, Emmanuelle Ferrant, et al.
Haematologica
|
May 15, 2025
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study
Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2024
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort
Amélie Anota, Mathurine Basset, Emilie Charton, et al.
Hemasphere
|
May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group
Pierre Sesques, Guillaume Manson, Guillaume Cartron, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Journal of Thrombosis and Thrombolysis
|
November 24, 2021
Management of bone marrow biopsy related bleeding risks: a retrospective observational study
Lucile Grange, Martin Killian, Emmanuelle Tavernier, et al.
Cancer Epidemiology
|
August 15, 2025
Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA
Christelle Cantrelle, Aurélien Belot, Alain Monnereau, et al.
Cancer Epidemiology
|
April 6, 2025
Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort
Christelle Cantrelle, Aurélien Belot, Alain Monnereau, et al.
Blood Cancer Journal
|
November 3, 2025
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials
Valentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, et al.
Leukemia
|
April 24, 2025
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Nicolas Gazeau, David Beauvais, Rémi Tilmont, et al.
Blood Advances
|
December 8, 2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
Raphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, et al.
Clinical Nuclear Medicine
|
June 11, 2021
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells
Pierre Sesques, Jérémie Tordo, Emmanuelle Ferrant, et al.
Haematologica
|
May 15, 2025
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study
Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2024
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort
Amélie Anota, Mathurine Basset, Emilie Charton, et al.
Hemasphere
|
May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group
Pierre Sesques, Guillaume Manson, Guillaume Cartron, et al.
Page
of 2